In his presentation at the J.P. Morgan Healthcare Conference, CEO Jacob Thaysen highlighted Illumina’s return to revenue growth, driven by strong demand across clinical, research and applied markets. The company serves more than 20,000 sequencing instruments globally and reported sequential improvements in instrument orders and consumable revenue in the fourth quarter of 2025. Management emphasized that workflow innovations and deeper penetration into clinical sequencing applications have accelerated consumable attach rates by over 15% year-over-year, underpinning a renewed growth trajectory.

On January 13, 2026, Illumina introduced the Billion Cell Atlas, the first tranche of its three-year program to build a 5 billion single-cell perturbation dataset. Under an alliance framework with AstraZeneca, Merck and Eli Lilly as founding participants, the Atlas will profile 1 billion individual cells across more than 200 disease-relevant cell lines using CRISPR genome-wide perturbations. The dataset is designed to validate genetic targets, train AI/ML models at scale and generate over 20 petabytes of single-cell transcriptomic data in its first year, all processed through Illumina’s DRAGEN pipeline and hosted on the Connected Analytics cloud platform.

Illumina’s newly established BioInsight division will commercialize the Atlas and future multi-billion-cell datasets, positioning the company at the intersection of genomics and AI. Thaysen outlined a disciplined capital allocation plan that prioritizes high-ROI R&D investments in single-cell and multiomics platforms, while maintaining operating margins consistent with long-term targets. By leveraging its installed base scale and ecosystem partnerships, Illumina expects the BioInsight business to contribute materially to non-instrument revenue growth by fiscal 2027 and generate incremental adjusted EBITDA margins above 25% as data products reach commercial scale.